血清MMP-9和ICAM-1水平对非小细胞肺癌骨转移诊断和预后的意义  

Diagnostic and prognostic significance of serum MMP-9,ICAM-1 in non-small cell lung cancer patients with bone metastasis

作　　者：卞晓洁[1] 陈平[2] 杨晨[3] 王智煜[3] 李洪涛[3] 沈赞[3] 姚阳[3] 赵晖[3] 

机构地区：[1]苏州大学附属第一人民医院急诊内科,214007 [2]上海交通大学附属瑞金医院消化内科,200233 [3]上海交通大学附属第六人民医院肿瘤科,上海200233

出　　处：《临床肿瘤学杂志》2010年第8期680-684,共5页Chinese Clinical Oncology

基　　金：国家自然科学基金(30872991);上海市浦江人才发展计划(08PJ14073)

摘　　要：目的探讨基质金属蛋白酶-9（MMP-9）和细胞间粘附分子-1（ICAM-1）在非小细胞肺癌（NSCLC）伴骨转移患者血清中的表达及其对预后的意义。方法用ELISA方法检测10例健康对照者和70例初治NSCLC患者空腹血MMP-9和ICAM-1的表达,其中40例NSCLC患者伴骨转移Ⅳ期,30例Ⅰ-Ⅱ期。结果伴骨转移Ⅳ期NSCLC患者血清MMP-9、ICAM-1水平高于Ⅰ-Ⅱ期NSCLC患者,且两者均高于健康对照者。血清MMP-9、ICAM-1水平与Ⅳ期伴骨转移患者的中位生存期显著相关,且血清MMP-9水平可作为Ⅳ期伴骨转移NSCLC的独立预后因素。结论 MMP-9和ICAM-1均伴随NSCLC的发生发展以及疾病的进展而升高,对MMP-9和ICAM-1表达的分析有助于评估Ⅳ期伴骨转移NSCLC患者的预后,同时积极针对患者转移灶的治疗可以明显延长Ⅳ期伴骨转移NSCLC患者生存期。Objective To investigate the diagnostic and prognostic value of matrix metalloproteinases-9（MMP-9） and intercellular adhesion molecule-1（ICAM-1） in serum for stage Ⅳ non-small cell lung cancer（NSCLC） patients with bone metastasis.Methods ELISA method was used to measure MMP-9 and ICAM-1 concentrations of 40 stage Ⅳ and 30 stage Ⅰ/Ⅱ NSCLC patients of initial treatment and 10 controls.Results Serum levels of MMP-9 and ICAM-1 in patients of stage Ⅳ NSCLC were higher than that of stage Ⅰ/Ⅱ,also of the control.The concentrations of MMP-9 and ICAM-1 were significantly correlated with survival time.Cox regression analysis found that MMP-9 could be an independent prognostic factor for the stage Ⅳ patients with bone metastasis.Conclusion MMP-9 and ICAM-1 are involved in the progression of NSCLC.The serum levels of MMP-9 and ICAM-1 might be a helpful role in estimating the prognosis of stage Ⅳ NSCLC patients with bone metastasis.Furthermore,the use of efficious therapeutic strategies can contribute to longer survival time.

关 键 词：MMP-9 ICAM-1 非小细胞肺癌 预后 

分 类 号：R734.2[医药卫生—肿瘤]